As filed with the Securities and Exchange Commission on December 27, 2023
Registration No. 333-259171
Registration No. 333-266812
Registration No. 333-273965
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO:
FORM S-8 REGISTRATION STATEMENT NO. 333-259171
FORM S-8 REGISTRATION STATEMENT NO. 333-266812
FORM S-8 REGISTRATION STATEMENT NO. 333-273965
UNDER
THE
SECURITIES ACT OF 1933
POINT BIOPHARMA GLOBAL INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
85-0800493 |
(State or other jurisdiction
of incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
4850 West 78th Street
Indianapolis, IN, 46268
(317) 543-9957
(Address, including zip code, and telephone number, including area code of registrants principal executive offices)
POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the 2021 Plan)
POINT Biopharma Inc. 2020 Equity Incentive Plan (the 2020 Plan)
(Full Titles of the Plans)
Philip L. Johnson
President
Point
Biopharma Global Inc.
Lilly Corporate Center
Indianapolis, Indiana 46285
Telephone: (317) 276-2000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Sophia Hudson, P.C.
Asher Qazi
Kirkland & Ellis LLP
601 Lexington Avenue
New
York, New York 10022
Telephone: (212) 446-4800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐